{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:13:07Z","timestamp":1770009187344,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019F00130"],"award-info":[{"award-number":["75N91019F00130"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Previous herpes simplex virus type 2 (HSV-2) vaccines have not prevented genital herpes. Concerns have been raised about the choice of antigen, the type of antibody induced by the vaccine, and whether antibody is present in the genital tract where infection occurs. We reported results of a trial of an HSV-2 replication-defective vaccine, HSV529, that induced serum neutralizing antibody responses in 78% of HSV-1\u2013\/HSV-2\u2013 vaccine recipients. Here we show that HSV-1\u2013\/HSV-2\u2013 vaccine recipients developed antibodies to epitopes of several viral proteins; however, fewer antibody epitopes were detected in vaccine recipients compared with naturally infected persons. HSV529 induced antibodies that mediated HSV-2\u2013specific natural killer (NK) cell activation. Depletion of glycoprotein D (gD)\u2013binding antibody from sera reduced neutralizing titers by 62% and NK cell activation by 81%. HSV-2 gD antibody was detected in cervicovaginal fluid at about one-third the level of that in serum. A vaccine that induces potent serum antibodies transported to the genital tract might reduce HSV genital infection.<\/jats:p>","DOI":"10.1093\/infdis\/jiab139","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T20:09:53Z","timestamp":1615579793000},"page":"1509-1519","source":"Crossref","is-referenced-by-count":6,"title":["Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus\u2013Seronegative Recipients of the HSV529 Vaccine"],"prefix":"10.1093","volume":"224","author":[{"given":"Kening","family":"Wang","sequence":"first","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesia","family":"Dropulic","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Bozekowski","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harlan L","family":"Pietz","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinthujan","family":"Jegaskanda","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennichi","family":"Dowdell","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua S","family":"Vogel","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Garabedian","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makinna","family":"Oestreich","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mir A","family":"Ali","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Lumbard","sequence":"additional","affiliation":[{"name":"Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Hunsberger","sequence":"additional","affiliation":[{"name":"Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Reifert","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston A","family":"Haynes","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaymie R","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Shon","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S","family":"Daugherty","sequence":"additional","affiliation":[{"name":"Serimmune, Santa Barbara, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I","family":"Cohen","sequence":"additional","affiliation":[{"name":"Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2021111805071868400_CIT0001","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1093\/clind\/13.Supplement_11.S950","article-title":"Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus","volume":"13","author":"Kohl","year":"1991","journal-title":"Rev Infect Dis"},{"key":"2021111805071868400_CIT0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/155.1.28","article-title":"Humoral and cell-mediated immunity in neonates with herpes simplex virus infection","volume":"155","author":"Sullender","year":"1987","journal-title":"J Infect Dis"},{"key":"2021111805071868400_CIT0003","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/iai.29.2.532-538.1980","article-title":"Relationship of antibody to outcome in neonatal herpes simplex virus infections","volume":"29","author":"Yeager","year":"1980","journal-title":"Infect Immun"},{"key":"2021111805071868400_CIT0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM198701293160503","article-title":"Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections","volume":"316","author":"Prober","year":"1987","journal-title":"N Engl J Med"},{"key":"2021111805071868400_CIT0005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"2021111805071868400_CIT0006","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: 2 randomized controlled trials. Chiron HSV vaccine study Group","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"2021111805071868400_CIT0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"2021111805071868400_CIT0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/jvi.61.2.264-268.1987","article-title":"Detection of asymptomatic herpes simplex virus infections after vaccination","volume":"61","author":"Ashley","year":"1987","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/315208","article-title":"Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine","volume":"181","author":"Kohl","year":"2000","journal-title":"J Infect Dis"},{"key":"2021111805071868400_CIT0010","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (HSV) type 2 vaccine, HSV529, in adults with or without HSV infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J Infect Dis"},{"key":"2021111805071868400_CIT0011","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1128\/JVI.01845-15","article-title":"A herpes simplex virus 2 (HSV-2) gD mutant impaired for neural tropism is superior to an HSV-2 gD subunit vaccine to protect animals from challenge with HSV-2","volume":"90","author":"Wang","year":"2016","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0012","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00350-08","article-title":"Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay","volume":"16","author":"Burbelo","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"2021111805071868400_CIT0013","doi-asserted-by":"crossref","first-page":"e00411-17","DOI":"10.1128\/JVI.00411-17","article-title":"Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0014","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1038\/s41598-020-62256-9","article-title":"Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology","volume":"10","author":"Kamath","year":"2020","journal-title":"Sci Rep"},{"key":"2021111805071868400_CIT0015","doi-asserted-by":"crossref","first-page":"205313","DOI":"10.1155\/2012\/205313","article-title":"Prediction and identification of potential immunodominant epitopes in glycoproteins B, C, E, G, and I of herpes simplex virus type 2","volume":"2012","author":"Pan","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2021111805071868400_CIT0016","doi-asserted-by":"crossref","first-page":"12612","DOI":"10.1128\/JVI.01930-14","article-title":"Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans","volume":"88","author":"Cairns","year":"2014","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0017","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1128\/jvi.61.11.3607-3611.1987","article-title":"Structural properties and reactivity of N-terminal synthetic peptides of herpes simplex virus type 1 glycoprotein D by using antipeptide antibodies and group VII monoclonal antibodies","volume":"61","author":"Bosch","year":"1987","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0018","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1128\/jvi.63.5.2325-2334.1989","article-title":"Fine mapping of antigenic site II of herpes simplex virus glycoprotein D","volume":"63","author":"Isola","year":"1989","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0019","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1128\/JVI.72.5.3595-3601.1998","article-title":"Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM","volume":"72","author":"Nicola","year":"1998","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0020","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/jvi.62.9.3474-3483.1988","article-title":"Use of synthetic peptides to map the antigenic determinants of glycoprotein D of herpes simplex virus","volume":"62","author":"Strynadka","year":"1988","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0021","doi-asserted-by":"crossref","first-page":"e1006430","DOI":"10.1371\/journal.ppat.1006430","article-title":"Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging","volume":"13","author":"Cairns","year":"2017","journal-title":"PLoS Pathog"},{"key":"2021111805071868400_CIT0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-020-0184-7","article-title":"Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity","volume":"5","author":"Burn Aschner","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2021111805071868400_CIT0023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1128\/jcm.22.4.641-644.1985","article-title":"Detection of herpes simplex virus type 2-specific antibody with glycoprotein G","volume":"22","author":"Lee","year":"1985","journal-title":"J Clin Microbiol"},{"key":"2021111805071868400_CIT0024","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1099\/0022-1317-80-7-1789","article-title":"Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1","volume":"80","author":"Grabowska","year":"1999","journal-title":"J Gen Virol"},{"key":"2021111805071868400_CIT0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-9071(199809)56:1<79::AID-JMV13>3.0.CO;2-R","article-title":"Identification of an immunodominant sequential epitope in glycoprotein G of herpes simplex virus type 2 that is useful for serotype-specific diagnosis","volume":"56","author":"Marsden","year":"1998","journal-title":"J Med Virol"},{"key":"2021111805071868400_CIT0026","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.xphs.2018.08.018","article-title":"Detection of residual proteins UL5 and UL29 using a targeted proteomics approach in HSV529, a replication-deficient HSV-2 vaccine candidate","volume":"107","author":"James","year":"2018","journal-title":"J Pharm Sci"},{"key":"2021111805071868400_CIT0027","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.3390\/v6114358","article-title":"Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis","volume":"6","author":"G\u00f6rander","year":"2014","journal-title":"Viruses"},{"key":"2021111805071868400_CIT0028","doi-asserted-by":"crossref","first-page":"e02309-18","DOI":"10.1128\/JVI.02309-18","article-title":"Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4(+) and CD8(+) T(RM) cells associated with protection against recurrent genital herpes","volume":"93","author":"Srivastava","year":"2019","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0029","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/JVI.05194-11","article-title":"Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling","volume":"86","author":"Kalantari-Dehaghi","year":"2012","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0030","first-page":"252","article-title":"Immunoprecipitation of herpes simplex virus polypeptides with human sera is related to their ELISA titre","volume":"35","author":"Mur\u00e1nyiov\u00e1","year":"1991","journal-title":"Acta Virol"},{"key":"2021111805071868400_CIT0031","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0042-6822(88)90556-9","article-title":"Characterization of epitopes on native and denatured forms of herpes simplex virus glycoprotein B","volume":"164","author":"Chapsal","year":"1988","journal-title":"Virology"},{"key":"2021111805071868400_CIT0032","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.vaccine.2010.01.030","article-title":"Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein","volume":"28","author":"Reszka","year":"2010","journal-title":"Vaccine"},{"key":"2021111805071868400_CIT0033","doi-asserted-by":"crossref","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"eLife"},{"key":"2021111805071868400_CIT0034","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1285-1","article-title":"Migrant memory B cells secrete luminal antibody in the vagina","volume":"571","author":"Oh","year":"2019","journal-title":"Nature"},{"key":"2021111805071868400_CIT0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/JVI.02380-14","article-title":"Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB\/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge","volume":"89","author":"\u00c7uburu","year":"2015","journal-title":"J Virol"},{"key":"2021111805071868400_CIT0036","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature11522","article-title":"A vaccine strategy that protects against genital herpes by establishing local memory T cells","volume":"491","author":"Shin","year":"2012","journal-title":"Nature"},{"key":"2021111805071868400_CIT0037","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection","volume":"108","author":"Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021111805071868400_CIT0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/515611","article-title":"Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine","volume":"178","author":"Ashley","year":"1998","journal-title":"J Infect Dis"},{"key":"2021111805071868400_CIT0039","doi-asserted-by":"crossref","first-page":"e00614","DOI":"10.1128\/IAI.00614-17","article-title":"B Cell presentation of chlamydia antigen selects out protective CD4\u03b313 T cells: implications for genital tract tissue-resident memory lymphocyte clusters","volume":"86","author":"Johnson","year":"2018","journal-title":"Infect Immun"},{"key":"2021111805071868400_CIT0040","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"key":"2021111805071868400_CIT0041","first-page":"388","article-title":"Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2","volume":"10","author":"Mbopi-K\u00e9ou","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"2021111805071868400_CIT0042","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"key":"2021111805071868400_CIT0043","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/hv.4529","article-title":"Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines","volume":"3","author":"Schwartz","year":"2007","journal-title":"Hum Vaccin"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab139\/40074942\/jiab139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/9\/1509\/41159943\/jiab139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/9\/1509\/41159943\/jiab139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:40:15Z","timestamp":1637221215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/9\/1509\/6170962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,3,15]]},"published-print":{"date-parts":[[2021,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab139","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,3,15]]}}}